ExploreWatchlistsPricing
  1. JP-listed companies
  2. CellSeed Inc.
  3. Financials
  4. Cash and cash equivalents

CellSeed Inc. (7776)

Market cap
¥8.3B
P/E ratio
-7.1x
Cellseed develops cell sheet regenerative medicine technology to treat diseases that conventional therapies cannot cure, serving researchers and patients globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 20251,319-38.20%
Dec 31, 20242,134-1.34%
Dec 31, 20232,163+101.76%
Dec 31, 20221,072+15.17%
Dec 31, 2021931-36.27%
Dec 31, 20201,461+37.16%
Dec 31, 20191,065+0.68%
Dec 31, 20181,058-21.65%
Dec 31, 20171,350+27.81%
Dec 31, 20161,056-48.91%
Dec 31, 20152,068-29.23%
Dec 31, 20142,921

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat